Bristol-Myers Squibb (BMY) Debt to Equity (2008 - 2026)
Bristol-Myers Squibb (BMY) debt to equity from Dec 31, 2008 to Mar 31, 2026. The current Bristol-Myers Squibb (BMY) debt to equity is 219.95%. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Debt to Equity
Debt to Equity
Annual Debt to Equity change of Bristol-Myers Squibb (BMY)
| Year | Debt to Equity | Change |
|---|---|---|
| 2025 | 242.66% | -19.81% |
| 2024 | 302.61% | +125.31% |
| 2023 | 134.31% | +7.09% |
| 2022 | 125.41% | +1.60% |
| 2021 | 123.43% | -7.25% |
| 2020 | 133.09% | +49.84% |
| 2020 | 88.82% | -5.30% |
| 2020 | 93.79% | +1.66% |
| 2020 | 92.25% | +3.14% |
| 2019 | 89.44% | -34.89% |
| 2019 | 137.38% | -9.19% |
| 2019 | 151.28% | +311.20% |
| 2019 | 36.79% | -25.14% |
| 2018 | 49.14% | +18.81% |
| 2018 | 41.36% | -9.43% |
| 2018 | 45.67% | +2.06% |
| 2018 | 44.75% | -24.68% |
| 2017 | 59.41% | +26.90% |
| 2017 | 46.82% | +0.40% |
| 2017 | 46.63% | -6.35% |
| 2017 | 49.79% | +24.59% |
| 2016 | 39.96% | N/A |
| 2016 | 0.00% | N/A |
| 2016 | 0.00% | N/A |
| 2016 | 0.00% | -100.00% |
| 2015 | 46.89% | +7.98% |
| 2015 | 43.42% | +0.38% |
| 2015 | 43.26% | -4.77% |
| 2015 | 45.43% | -13.86% |
| 2014 | 52.73% | +10.31% |
| 2014 | 47.81% | -0.27% |
| 2014 | 47.94% | +1.06% |
| 2014 | 47.43% | -13.81% |
| 2013 | 55.03% | +23.41% |
| 2013 | 44.60% | -10.00% |
| 2013 | 49.55% | -5.46% |
| 2013 | 52.41% | -3.43% |
| 2012 | 54.28% | +4.39% |
| 2012 | 51.99% | +57.82% |
| 2012 | 32.94% | +1.56% |
| 2012 | 32.44% | -5.74% |
| 2011 | 34.41% | +4.03% |
| 2011 | 33.08% | +0.16% |
| 2011 | 33.03% | -0.47% |
| 2011 | 33.18% | -4.25% |
| 2010 | 34.65% | -19.14% |
| 2009 | 42.86% | -22.16% |
| 2008 | 55.05% | N/A |
Comparison Bristol-Myers Squibb (BMY) debt to equity with competitors
Bristol-Myers Squibb (BMY) debt to equity is 219.95%.
| Ticker | Name | Debt to Equity | Upside |
|---|---|---|---|
| SNY | Sanofi | 27.50% | -87.50% |
| BIIB | Biogen Inc | 33.72% | -84.67% |
| JNJ | Johnson & Johnson | 67.73% | -69.21% |
| PFE | Pfizer Inc | 71.50% | -67.49% |
| AZN | Astrazeneca plc | 71.66% | -67.42% |
| NVO | Novo Nordisk | 72.09% | -67.23% |
| GILD | Gilead Sciences Inc | 94.30% | -57.13% |
| GSK | GSK Plc | 106.74% | -51.47% |
| MRK | Merck & Co Inc | 107.06% | -51.33% |
| NVS | Novartis AG | 122.03% | -44.52% |
| LLY | Lilly(Eli) & Company | 139.02% | -36.80% |
| MDCX | MDCorp | 176.75% | -19.64% |
| MDCXW | Medicus Pharma Ltd warrant | 176.75% | -19.64% |
| GRFS | Grifols SA | 177.15% | -19.46% |
| AMGN | AMGEN Inc | 623.75% | +183.59% |
| OGN | Organon & Company | 948.95% | +331.43% |